PUBLISHER: The Business Research Company | PRODUCT CODE: 1720928
PUBLISHER: The Business Research Company | PRODUCT CODE: 1720928
Vyndaqel, also known as tafamidis, is a medication used to treat transthyretin amyloid cardiomyopathy (ATTR-CM), a heart condition caused by the accumulation of misfolded transthyretin proteins. It works by stabilizing the transthyretin protein, preventing its misfolding and buildup in the heart. Vyndaqel helps reduce cardiovascular-related deaths and hospitalizations while improving the quality of life for patients with this progressive and potentially fatal disease.
The primary product types of Vyndaqel include Vyndaqel (tafamidis 20 mg) and Vyndamax (tafamidis 61 mg). Vyndaqel (tafamidis 20 mg) is a transthyretin stabilizer used to treat transthyretin amyloid polyneuropathy (ATTR-PN) by slowing disease progression. It is indicated for familial amyloid polyneuropathy (FAP) and wild-type or hereditary transthyretin-mediated amyloidosis cardiomyopathy (ATTR-CM). Vyndaqel is distributed through hospital pharmacies, online pharmacies, and retail pharmacies.
The vyndaqel market research report is one of a series of new reports from The Business Research Company that provides vyndaqel market statistics, including vyndaqel industry global market size, regional shares, competitors with a vyndaqel market share, detailed vyndaqel market segments, market trends and opportunities, and any further data you may need to thrive in the vyndaqel industry. This vyndaqel market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The vyndaqel market size has grown rapidly in recent years. It will grow from $1.62 billion in 2024 to $1.91 billion in 2025 at a compound annual growth rate (CAGR) of 18.1%. The growth during the historic period can be attributed to increasing awareness of transthyretin amyloidosis, a rising prevalence of transthyretin-mediated amyloidosis cardiomyopathy, a greater focus on rare diseases, growing government support, an increase in clinical trials, and a growing geriatric population.
The vyndaqel market size is expected to see rapid growth in the next few years. It will grow to $3.67 billion in 2029 at a compound annual growth rate (CAGR) of 17.1%. The projected growth in the forecast period is driven by increasing investment in research and development, the growing adoption of precision medicine, rising physician familiarity, greater availability of diagnostic tools, and expanding government initiatives. Key trends include the expansion of telemedicine facilities, strategic collaborations, advancements in genetic testing, the integration of digital health tools, and the rise of personalized medicine.
The increasing investment in research and development is expected to drive the growth of the Vyndaqel market in the coming years. Research and development involve innovating and enhancing products, services, or processes through systematic investigation and experimentation. The rise in R&D investment is attributed to the increasing prevalence of neurological disorders, advancements in medical technology, growing awareness and demand for innovative treatments, and significant funding initiatives from both government and private sectors. Investment in research and development accelerates the development and optimization of therapies, enhancing their efficacy and accessibility for patients. It fosters advancements in Vyndaqel, improving its effectiveness, availability, and potential for expanded indications. For example, in July 2024, the Department of Health and Social Care, a UK-based government department, reported that the business enterprise sector in the UK conducted pharmaceutical research and development worth approximately $11.1 billion in 2022, representing 0.36% of the nation's gross domestic product. As a result, increasing investment in research and development is fueling the expansion of the Vyndaqel market.
The growing adoption of precision medicine is also expected to contribute to the expansion of the Vyndaqel market. Personalized medicine involves tailoring medical treatments to individual patients based on their genetic, environmental, and lifestyle factors. The increasing adoption of personalized medicine is driven by advancements in genomic research, improved treatment efficacy, and the rising prevalence of chronic diseases. This approach benefits Vyndaqel by enabling more precise diagnosis and targeted treatment for transthyretin amyloidosis (ATTR), ensuring that the drug reaches patients who will benefit the most. By enhancing treatment efficacy and improving patient outcomes, the rising adoption of personalized medicine supports market growth and increases the demand for specialized therapies such as Vyndaqel. For instance, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that the US Food and Drug Administration (FDA) approved 16 novel personalized therapies for patients with rare diseases in 2023, a significant increase from six approvals in 2022. As a result, the increasing adoption of precision medicine is driving the growth of the Vyndaqel market.
Major companies in the Vyndaqel market are expanding their production facilities to manufacture active pharmaceutical ingredients (APIs). Facility expansion involves increasing physical infrastructure, production capacity, or operational capabilities to accommodate growth, enhance efficiency, and meet rising demand. For example, in July 2024, Pfizer Inc., a US-based pharmaceutical company that manufactures Vyndaqel, inaugurated a $1 billion plant in Singapore's Tuas Biomedical Park. This new 429,000 sq ft facility will produce active pharmaceutical ingredients for Pfizer's cancer, pain, and antibiotic medications. As an extension of Pfizer's existing site, which has been operational for 20 years, the new facility is expected to create 250 highly skilled jobs. The plant has also been awarded a Green Mark Gold certification for its environmental sustainability efforts and aligns with Pfizer's commitment to achieving net-zero emissions by 2040.
The key player in the vyndaqel market is Pfizer Inc.
North America was the largest region in the vyndaqel market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in vyndaqel report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the vyndaqel market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The vyndaqel market consists of sales of cardiovascular medications, neuropathy medications, anticoagulants and diuretics. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Vyndaqel Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on vyndaqel market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for vyndaqel ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The vyndaqel market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.